Menu Menu


AZNCF Financials       Clear


AZNCF        0000901832    
Filing Date Form Type Description Document
2021-02-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-02-16 6-K ANNUAL FINANCIAL REPORT View Document
2021-02-16 20-F 20-F View Document
2021-02-12 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 425 425 View Document
2021-02-11 6-K ASTRAZENECA NON-EXECUTIVE BOARD CHANGES View Document
2021-02-11 6-K AZN: FULL-YEAR 2020 RESULTS View Document
2021-02-10 SC 13G SC 13G View Document
2021-02-10 SC 13G/A SC 13G/A View Document
2021-02-10 6-K DIVESTMENT OF CRESTOR IN EUROPE COMPLETED View Document
2021-02-05 6-K UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI View Document
2021-02-04 6-K FORXIGA APPROVED IN CHINA FOR HEART FAILURE View Document
2021-02-03 SC 13G/A SEC SCHEDULE 13G View Document
2021-02-01 6-K TOTAL VOTING RIGHTS View Document
2021-02-01 6-K ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING View Document
2021-02-01 6-K COVID-19 VACCINE AUTHORISED FOR USE BY THE EU View Document
2021-01-29 6-K COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU View Document
2021-01-29 SC 13G/A View Document
2021-01-26 6-K BLOCK LISTING APPLICATION View Document
2021-01-26 6-K SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA View Document
2021-01-25 6-K CALQUENCE APPROVED IN JAPAN FOR CLL View Document
2021-01-25 6-K CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB View Document
2021-01-20 6-K ENHERTU APPROVED IN THE EU FOR BREAST CANCER View Document
2021-01-19 6-K ENHERTU APPROVED IN THE US FOR GASTRIC CANCER View Document
2021-01-15 6-K IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO View Document
2021-01-06 6-K FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR View Document
2021-01-04 6-K TOTAL VOTING RIGHTS View Document
2021-01-04 6-K ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED View Document
2020-12-30 6-K ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK View Document
2020-12-29 6-K LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P View Document
2020-12-21 6-K TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST View Document
2020-12-21 6-K UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS View Document
2020-12-18 425 425 View Document
2020-12-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-12-17 425 425 View Document
2020-12-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-12-15 425 425 View Document
2020-12-15 6-K IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 425 425 View Document
2020-12-14 6-K TRASTUZUMAB DERUXTECAN POSITIVE CHMP View Document
2020-12-14 6-K TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD View Document
2020-12-14 6-K ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC View Document
2020-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2020-12-01 6-K TOTAL VOTING RIGHTS View Document
2020-12-01 6-K CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE View Document
2020-11-30 6-K FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE View Document
2020-11-23 6-K AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 View Document
2020-11-20 6-K IMFINZI NEW DOSING APPROVED IN THE US View Document
2020-11-13 25-NSE View Document
2020-11-10 6-K TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2020-11-09 6-K CALQUENCE APPROVED IN THE EU FOR CLL View Document
2020-11-06 6-K BRILINTA APPROVED IN THE US IN STROKE View Document
2020-11-05 6-K AZN: YEAR-TO-DATE AND Q3 2020 RESULTS View Document
2020-11-05 6-K FORXIGA APPROVED IN THE EU FOR HEART FAILURE View Document
2020-11-05 6-K LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F View Document
2020-11-05 6-K LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT View Document
2020-11-02 6-K TOTAL VOTING RIGHTS View Document
2020-10-30 6-K ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES View Document
2020-10-29 6-K DIRECTORATE CHANGE View Document
2020-10-28 6-K ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET View Document
2020-10-28 6-K FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA View Document
2020-10-20 6-K TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW View Document
2020-10-19 6-K FORXIGA HF RECEIVES POSITIVE CHMP OPINION View Document
2020-10-19 6-K TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION View Document
2020-10-13 6-K COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING View Document
2020-10-02 6-K FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE View Document
2020-10-01 6-K TOTAL VOTING RIGHTS View Document
2020-09-25 6-K DIRECTORATE CHANGE View Document
2020-09-24 CERT View Document
2020-09-24 8-A12B 8-A12B View Document
2020-09-24 25 25 View Document
2020-09-21 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC View Document
2020-09-21 6-K LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT View Document
2020-09-21 6-K TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV View Document
2020-09-10 6-K ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ View Document
2020-09-10 6-K FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I View Document
2020-09-01 6-K TOTAL VOTING RIGHTS View Document
2020-09-01 6-K IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER View Document
2020-09-01 6-K FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH View Document
2020-08-25 6-K PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE View Document
2020-08-21 6-K IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C View Document
2020-08-18 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE View Document
2020-08-12 CERT NYSE CERTIFICATION View Document
2020-08-06 8-A12B FORM 8-A12B View Document
2020-08-06 6-K FORM 6-K View Document
2020-08-05 424B2 FORM 424B2 View Document
2020-08-04 6-K ASTRAZENECA PRICES A $3BN BOND ISSUE View Document
2020-08-04 FWP FORM FWP View Document
2020-08-03 S-8 S-8 View Document
2020-08-03 6-K TOTAL VOTING RIGHTS View Document
2020-08-03 FWP FORM FWP View Document
2020-08-03 424B2 FORM 424B2 View Document
2020-07-31 6-K/A 6-K/A View Document
2020-07-30 6-K AZN: H1 2020 RESULTS View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas